Sesen Bio Inc
F:PCBK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shell PLC
NYSE:SHEL
|
UK |
|
O
|
Omesti Bhd
KLSE:OMESTI
|
MY |
|
D
|
Dida Inc
HKEX:2559
|
CN |
|
Standex International Corp
NYSE:SXI
|
US |
|
Hindustan Copper Ltd
NSE:HINDCOPPER
|
IN |
|
Lundin Mining Corp
TSX:LUN
|
CA |
|
Jyothy Labs Ltd
BSE:532926
|
IN |
|
Constellium SE
NYSE:CSTM
|
FR |
|
Niigata Kotsu Co Ltd
TSE:9017
|
JP |
Sesen Bio Inc
EPS (Diluted)
Sesen Bio Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sesen Bio Inc
F:PCBK
|
EPS (Diluted)
-$1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Sesen Bio Inc
Glance View
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
See Also
What is Sesen Bio Inc's EPS (Diluted)?
EPS (Diluted)
-2
USD
Based on the financial report for Dec 31, 2022, Sesen Bio Inc's EPS (Diluted) amounts to -2 USD.
What is Sesen Bio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
-4 850%
Over the last year, the EPS (Diluted) growth was -4 850%.
